Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 06, 2020 Filed Nov 10, 2020 23:04 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 15,375 | $302.47 | $4,650,476.25 |
DisclosureSEC source: 0000914190-20-000399 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,269 F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:04 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 25,157 | $86.25 | $2,169,791.25 |
DisclosureSEC source: 0000914190-20-000399 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC |
STEER RANDOLPH CDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $66.90 | $0.00 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · derivative · entry 10 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC |
STEER RANDOLPH CDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $70.35 | $0.00 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · derivative · entry 9 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC |
STEER RANDOLPH CDirector
|
SaleCommon Stock | 2,535 | $304.59 | $772,135.65 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · nonDerivative · entry 8 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,112 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $304.59 to $304.67, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC |
STEER RANDOLPH CDirector
|
SaleCommon Stock | 975 | $304.14 | $296,536.50 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · nonDerivative · entry 7 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,647 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $303.47 to $304.46, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC |
STEER RANDOLPH CDirector
|
SaleCommon Stock | 1,195 | $302.31 | $361,260.45 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · nonDerivative · entry 6 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,622 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $302.00 to $302.67, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC |
STEER RANDOLPH CDirector
|
SaleCommon Stock | 1,801 | $301.78 | $543,505.78 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · nonDerivative · entry 5 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,817 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $301.00 to $301.98, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC |
STEER RANDOLPH CDirector
|
SaleCommon Stock | 1,771 | $299.96 | $531,229.16 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · nonDerivative · entry 4 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,618 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $299.70 to $300.42, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC |
STEER RANDOLPH CDirector
|
SaleCommon Stock | 1,723 | $299.06 | $515,280.38 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · nonDerivative · entry 3 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,389 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $298.49 to $299.30, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC |
STEER RANDOLPH CDirector
|
Exercise / conversionCommon Stock | 5,000 | $66.90 | $334,500.00 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · nonDerivative · entry 2 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC |
STEER RANDOLPH CDirector
|
Exercise / conversionCommon Stock | 5,000 | $70.35 | $351,750.00 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 21:53 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $70.35 | $0.00 |
DisclosureSEC source: 0001562180-20-006646 · primarydocument.xml · derivative · entry 5 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 21:53 UTC |
HIGGINS JOHN LDirector
|
SaleCommon Stock | 3,100 | $301.06 | $933,300.57 |
DisclosureSEC source: 0001562180-20-006646 · primarydocument.xml · nonDerivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,412 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $300.9950 to $301.0647, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 21:53 UTC |
HIGGINS JOHN LDirector
|
SaleCommon Stock | 450 | $299.84 | $134,927.64 |
DisclosureSEC source: 0001562180-20-006646 · primarydocument.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,512 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $299.6050 to $300.4491, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 21:53 UTC |
HIGGINS JOHN LDirector
|
SaleCommon Stock | 1,450 | $298.98 | $433,515.93 |
DisclosureSEC source: 0001562180-20-006646 · primarydocument.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,962 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $298.5100 to $299.2800, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 21:53 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionCommon Stock | 5,000 | $70.35 | $351,750.00 |
DisclosureSEC source: 0001562180-20-006646 · primarydocument.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 100 | $293.66 | $29,366.00 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · nonDerivative · entry 16 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,137 F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.66 to $293.66, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 750 | $291.06 | $218,297.03 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · nonDerivative · entry 15 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,237 F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $290.66 to $291.40, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 359 | $289.39 | $103,889.50 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · nonDerivative · entry 14 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,987 F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $289.00 to $289.58, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 3,249 | $287.98 | $935,648.32 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · nonDerivative · entry 13 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,346 F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $287.68 to $288.46, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 121 | $287.15 | $34,745.07 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · nonDerivative · entry 12 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,595 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $286.67 to $287.25, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,630 | $285.12 | $464,739.90 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · nonDerivative · entry 11 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,716 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $285.00 to $285.89, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 325 | $283.64 | $92,183.00 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · nonDerivative · entry 10 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,346 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $283.57 to $284.48, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,674 | $282.52 | $472,938.98 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · nonDerivative · entry 9 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,671 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.00 to $282.78, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 203 | $281.27 | $57,098.64 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · nonDerivative · entry 8 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,345 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.00 to $281.55, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 398 | $280.28 | $111,550.25 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · nonDerivative · entry 7 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,548 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $279.84 to $280.80, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 8,809 | $108.49 | $955,688.41 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · nonDerivative · entry 6 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2020 Filed Nov 12, 2020 21:17 UTC Amendment |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 8,809 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0000914190-20-000401 · edgar.xml · derivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,809 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This amendment is being filed solely to correct a typographical error in the Transaction Date. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,100 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · derivative · entry 17 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,100 Underlying: Common Stock · 7,100 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,200 | $275.79 | $330,951.72 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · nonDerivative · entry 5 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,137 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.38 to $276.30, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,600 | $274.53 | $439,254.40 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · nonDerivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,337 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.24 to $275.045, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 2,745 | $273.65 | $751,156.62 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,937 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.23 to $274.19, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,555 | $272.71 | $424,063.89 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,682 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.21 to $273.20, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 7,100 | $108.49 | $770,279.00 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 21:23 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $255.69 | $0.00 |
DisclosureSEC source: 0001562180-20-006501 · primarydocument.xml · derivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507 Underlying: Common Stock · 1,507 shares Expires 2030-10-29 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/29/2020) or the date of Bio-Techne's 2021 annual meeting of shareholders. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 21:23 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantCommon Stock | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006501 · primarydocument.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,612 Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 21:19 UTC |
STEER RANDOLPH CDirector
|
GrantStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $255.69 | $0.00 |
DisclosureSEC source: 0001562180-20-006500 · primarydocument.xml · derivative · entry 2 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507 Underlying: Common Stock · 1,507 shares Expires 2030-10-29 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/29/2020) or the date of Bio-Techne's 2021 annual meeting of shareholders. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 21:19 UTC |
STEER RANDOLPH CDirector
|
GrantCommon Stock | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006500 · primarydocument.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,112 Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 20:20 UTC |
Nusse RoelandDirector
|
GrantStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $255.69 | $0.00 |
DisclosureSEC source: 0001562180-20-006492 · primarydocument.xml · derivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507 Underlying: Common Stock · 1,507 shares Expires 2030-10-29 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/29/2020) or the date of Bio-Techne's 2021 annual meeting of shareholders. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 20:20 UTC |
Nusse RoelandDirector
|
GrantCommon Stock | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006492 · primarydocument.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,765 Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 21:16 UTC |
Vessey RupertDirector
|
GrantStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $255.69 | $0.00 |
DisclosureSEC source: 0001562180-20-006499 · primarydocument.xml · derivative · entry 2 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507 Underlying: Common Stock · 1,507 shares Expires 2030-10-29 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/29/2020) or the date of Bio-Techne's 2021 annual meeting of shareholders. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 21:16 UTC |
Vessey RupertDirector
|
GrantCommon Stock | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006499 · primarydocument.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033 Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 20:17 UTC |
KEEGAN JOSEPH DDirector
|
GrantStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $255.69 | $0.00 |
DisclosureSEC source: 0001562180-20-006491 · primarydocument.xml · derivative · entry 2 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507 Underlying: Common Stock · 1,507 shares Expires 2030-10-29 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/29/2020) or the date of Bio-Techne's 2021 annual meeting of shareholders. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 20:17 UTC |
KEEGAN JOSEPH DDirector
|
GrantCommon Stock | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006491 · primarydocument.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,139 Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 20:15 UTC |
HIGGINS JOHN LDirector
|
GrantStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $255.69 | $0.00 |
DisclosureSEC source: 0001562180-20-006489 · primarydocument.xml · derivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507 Underlying: Common Stock · 1,507 shares Expires 2030-10-29 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/29/2020) or the date of Bio-Techne's 2021 annual meeting of shareholders. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 20:15 UTC |
HIGGINS JOHN LDirector
|
GrantCommon Stock | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006489 · primarydocument.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,412 Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 20:11 UTC |
Seth AlpnaDirector
|
GrantStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $255.69 | $0.00 |
DisclosureSEC source: 0001562180-20-006487 · primarydocument.xml · derivative · entry 2 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507 Underlying: Common Stock · 1,507 shares Expires 2030-10-29 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/29/2020) or the date of Bio-Techne 2021 annual meeting of shareholders. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 20:11 UTC |
Seth AlpnaDirector
|
GrantCommon Stock | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006487 · primarydocument.xml · nonDerivative · entry 1 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,139 Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 20:13 UTC |
Bushman Julie LDirector
|
GrantStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $255.69 | $0.00 |
DisclosureSEC source: 0001562180-20-006488 · primarydocument.xml · derivative · entry 2 Bushman Julie L · CIK 0001518599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507 Underlying: Common Stock · 1,507 shares Expires 2030-10-29 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/29/2020) or the date of Bio-Techne's 2021 annual meeting of shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.